It was reported on Sunday, that US-based Geneyork Pharmaceuticals in collaboration with Lannett Company, Geneyork's United States distribution and marketing partner, has commenced commercial shipment of a generic version of Deltasone (Prednisone) Tablets in the US.
The tablets come in 1mg, 2.5mg, 5mg, 10mg, 20mg, and 50mg doses.
The product is a corticosteroid aimed at the treatment of conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems and immune system disorders.
Isaac Liu, PhD, CEO of Geneyork, said, 'We are proud to add Prednisone Tablets to our growing portfolio of more than 40 specialty products. The launch of Prednisone Tablets demonstrates our strong development and partnership capabilities. Geneyork continues to expand its product development portfolio and has secured nine ANDA approvals and has an additional six filed with the FDA. We have also acquired or exclusively in licensed five ANDAs. We are pleased to partner with the Lannett for this launch.'
Natera announces receipt of positive Medicare coverage for Prospera DNA test
Lannett Company reports third quarter fiscal 2020 financial results
Fujifilm expands production of influenza antiviral drug Avigan for COVID-19
USFDA grants final approval to Cipla's Albuterol Sulfate Inhalation Aerosol
FDA approves generic albuterol inhaler for treating bronchospasm